|
GLRX3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.00730000399219E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.48389999574417E-08 |
| Normal-vs-Stage2 |
4.171400E-01 |
| Normal-vs-Stage3 |
3.97680000000511E-05 |
| Normal-vs-Stage4 |
2.11649999999342E-05 |
| Stage1-vs-Stage2 |
1.182420E-02 |
| Stage1-vs-Stage3 |
9.091400E-01 |
| Stage1-vs-Stage4 |
4.276000E-01 |
| Stage2-vs-Stage3 |
3.138100E-02 |
| Stage2-vs-Stage4 |
8.577600E-03 |
| Stage3-vs-Stage4 |
4.278200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.054599995167E-08 |
| Normal-vs-AfricanAmerican |
8.876000E-03 |
| Normal-vs-Asian |
6.16540000000221E-05 |
| Caucasian-vs-AfricanAmerican |
8.559000E-01 |
| Caucasian-vs-Asian |
4.381800E-01 |
| AfricanAmerican-vs-Asian |
4.745400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.986060E-04 |
| Normal-vs-Female |
1.62740000364536E-08 |
| Male-vs-Female |
4.316200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.24959997483654E-09 |
| Normal-vs-Age(41-60Yrs) |
9.74620000000481E-05 |
| Normal-vs-Age(61-80Yrs) |
1.139840E-03 |
| Normal-vs-Age(81-100Yrs) |
1.272810E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.518100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.028960E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.025000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.628000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.401600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.207400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.815900E-04 |
| Classical-VS-Follicular |
5.97450000583422E-09 |
| Classical-VS-Other |
3.260200E-01 |
| Classical-VS-Normal |
3.26090265900802E-11 |
| Tall-VS-Follicular |
7.12720005235923E-09 |
| Tall-VS-Other |
4.269600E-02 |
| Tall-VS-Normal |
9.72100000495857E-08 |
| Follicular-VS-Other |
2.893400E-01 |
| Follicular-VS-Normal |
3.980600E-01 |
| Other-VS-Normal |
5.060200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.540200E-03 |
| Normal-vs-N1 |
1.275800E-03 |
| N0-vs-N1 |
1.089000E-01 |
|
|
